Enhancement of bone healing using non-glycosylated rhBMP-2 released from a fibrin matrix in dogs and cats.
OBJECTIVE
To test a non-glycosylated recombinant human bone morphogenetic protein-2 (ngly-rhBMP-2)/fibrin composite, which has been shown experimentally to enhance healing of bone defects in rodents, in a clinical case series of dogs and cats undergoing treatment for fracture non-unions and arthrodesis.


METHODS
A ngly-rhBMP-2/fibrin composite was applied in 41 sites in 38 dogs and cats for which a cancellous bone autograft was indicated, replacing the graft.


RESULTS
Bridging of the bone defect with functional bone healing was achieved in 90 per cent of the arthrodesis and fracture nonunions treated in this manner.


CONCLUSIONS
This prospective clinical study demonstrates the beneficial effects of ngly-rhBMP-2 in a specially designed fibrin matrix on the treatment of bone defects, and validates the use of this composite as an alternative to bone autografts in dogs and cats.
Schmoekel
H G
HG
University of Bern, Department of Clinical Veterinary Medicine, Bern, Switzerland.
Weber
F E
FE
Hurter
K
K
Schense
J C
JC
Seiler
G
G
Ryrz
U
U
Spreng
D
D
Schawalder
P
P
Hubbell
J
J
D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D018786:Bone Substitutes; D002415:Cats / Q000293:injuries*; D004285:Dogs / Q000293:injuries*; D005260:Female; D005337:Fibrin; D005592:Fracture Fixation / Q000379:methods / Q000662:veterinary*; D017102:Fracture Healing / Q000187:drug effects*; D008297:Male; D011446:Prospective Studies; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*; D016896:Treatment Outcome
C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D016212:Transforming Growth Factor beta; D005337:Fibrin